NASH has become one of the most challenging conditions in medicine and there is an urgent need for a comprehensive public health response. However, the gap with awareness and knowledge is enormous and pharmacological intervention in NASH has been rather disappointing so far. To realize safe and efficient
pharmacological interventions, large-scale clinical trials are vital. Yet, most of the currently known NASH (F2/F3/F4) patients have already been approached to participate in previous or ongoing trials. Therefore, novel ways to identify potential candidates for studies are critically needed.

As a response to the NASH conundrum, Julius Clinical initiated: GRIP on NASH. A multinational program in which 10,000 patients at risk (with diabetes mellitus, obesity, hypertension or metabolic syndrome) are screened for the presence of NAFLD and NASH.

Do you want to know more about this groundbreaking research project? Fill in the form below and download our Factsheet!